New PET tracer could spot rare brain tumors without surgery

NCT ID NCT07177482

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 2 times

Summary

This study is testing a new radioactive tracer called 68Ga-MY6349 to see if it can help diagnose craniopharyngioma, a rare brain tumor, using PET/CT scans. The tracer targets a protein called Trop-2, which is often found on these tumors. Twenty participants with suspected or confirmed craniopharyngioma will receive one injection of the tracer and then undergo imaging. The goal is to see if the tracer can accurately detect the tumor and measure Trop-2 levels, potentially offering a non-invasive alternative to surgery for diagnosis.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

68Ga-MY6349 (a radioactive tracer for PET imaging)

What this could lead to

If successful, this could provide a non-invasive way to diagnose craniopharyngioma and assess Trop-2 expression, potentially guiding treatment decisions without needing a biopsy.

What could go wrong

This is a very small, early-phase study (20 participants) focused on imaging, not treatment. The tracer may not reliably distinguish craniopharyngioma from other conditions, and results may not generalize to larger populations.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CRANIOPHARYNGIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

craniopharyngioma disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beijing Tiantan Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100070, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••